RSS Feed For (NASDAQ:ARAY)

ACCURAY (NASDAQ:ARAY)

5.54 0.05 (0.89%)
ACCURAY (NASDAQ:ARAY) Delayed :
Previous Close $5.59    52 Week High $8.35 
Open $5.63    52 Week Low $3.78 
Day High $5.71    P/E 554.00 
Day Low $5.52    EPS $0.01 
Volume 108,733       
More ARAY Info: Chart SEC Filings Profile Historical Options

Accuray Summary

Accuray Incorporated designs, develops, and sells the CyberKnife system, an image-guided robotic radio surgery system for the treatment of solid tumors.

Executives

Euan Thomson - CEO, President
John Adler Jr. - Founder

Links

http://www.accuray.com/

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
AIR 3 ENTU 2
MXIM 2 COCO 2
MXIM 2 XOM 2
NED 2 ED 2
CYBS 2 XOM 2
WINN 2 PG 2
View All Friends, Peers and Foes

StreetInsider Reports on ARAY by Category

Comments on recent ARAY articles

Piper_Luvr
on Oct 23, 2008
at 08:45 PM
smart analysis Brilliant work Piper. Basically what you're saying is, "at first the units were only purchased by neurosurgeons, but the uses have expanded and now others are buying them, and they have a great product, that's why we're downgrading ARAY." The other brilliant part is, "focus on nearer-term indications such as lung and liver cancers while waiting for data on prostate applications to mature" This is a common misconception among everyone who didn't make it to page-4 of the annual report where a pretty color chart shows that since '06 lung and liver cancer treatments have tippled, pancreatic treatments have increased 50% and prostate treatments have increased almost 10-fold. Other than that, you were right on.
Article: Piper Jaffray & Co. Downgrades Accuray (ARAY) to Neutral

Comments on ARAY


No comments are currently available.